The Breast Cancer Continuum: Intersecting Current and Novel Treatment Strategies In Clinical Practice
Hematology-Oncology
Curriculum:
The Breast Cancer Continuum: Current and Novel Treatment Strategies
The Breast Cancer Continuum: Current and Novel Treatment Strategies
Credits:
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
September 04, 2014
September 04, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Surgeons, Medical oncologists, Radiation oncologists, Researchers, Oncology nurses and other healthcare providers involved in the treatment and management of patients with breast cancer.
Relevant Terms:
Breast Cancer
Edith A. Perez, MD
Edith A. Perez, MD
Deputy Director at Large, Mayo Clinic Cancer Center
Group Vice Chair, Alliance for Clinical Trials in Oncology
Serene M. and Frances C. Durling Professor of Medicine
Mayo Clinic - Jacksonville
Jacksonville, Florida
Bio
Edith A. Perez, MD, is the Deputy Director at Large for Mayo Clinic Cancer Center in Florida, Group Vice Chair of the Alliance for Clinical Trials in Oncology, Director of the Breast Program, and the Serene M. and Frances C. Durling Professor of Medicine at Mayo Medical School. She is also Chair of the Mayo Clinic Breast Cancer Translational Genomics Program started in 2009 and Chair of the Breast Cancer Specialty Council formed in 2012. She is a cancer specialist and an internationally known translational researcher at Mayo Clinic. Her roles extend nationally, including positions within Mayo Clinic, the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute.
Dr. Perez has developed, and is involved in, a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. She leads and has helped develop basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. She has authored more than 690 research articles in journals, books, and abstracts. Dr. Perez is invited frequently to lecture at national and international meetings. She serves on the editorial boards of multiple academic journals.
| 1. | Analyze key pathologic and molecular findings in the identification and diagnosis of early-stage, locally advanced, and metastatic breast cancers | 2. | Determine optimal sequencing and duration for individualized treatments for HER2+ patients with MBC |
| 3. | Evaluate the benefits of mTOR inhibitors, non-taxane microtubules, epothilones, antibody-drug conjugates, and other agents for MBC | 4. | Assess the optimal use of hormonal therapy in patients with breast cancer |
| 5. | Apply current and emerging evidence supporting VEGF and other targeted therapy in breast cancer treatment | 6. | Utilize prognostic assays in determining treatments for patients with breast cancer |
| 7. | Incorporate current treatment guidelines into decision-making for treating patients with breast cancer |
| 1. | Analyze key pathologic and molecular findings in the identification and diagnosis of early-stage, locally advanced, and metastatic breast cancers |
| 2. | Determine optimal sequencing and duration for individualized treatments for HER2+ patients with MBC |
| 3. | Evaluate the benefits of mTOR inhibitors, non-taxane microtubules, epothilones, antibody-drug conjugates, and other agents for MBC |
| 4. | Assess the optimal use of hormonal therapy in patients with breast cancer |
| 5. | Apply current and emerging evidence supporting VEGF and other targeted therapy in breast cancer treatment |
| 6. | Utilize prognostic assays in determining treatments for patients with breast cancer |
| 7. | Incorporate current treatment guidelines into decision-making for treating patients with breast cancer |
You are invited to participate in this CME/CE-certified virtual grand rounds activity entitled, "The Breast Cancer Continuum: Intersecting Current and Novel Treatment Strategies In Clinical Practice."
Estimated Time To Complete Activity: 1 hour
Estimated Time To Complete Activity: 1 hour
Fee Statement
There is no fee for this educational activity.
Virtual Grand Rounds Activity Agenda
There is no fee for this educational activity.
Virtual Grand Rounds Activity Agenda
- Introduction (5 mins)
- Component 1: What are some outstanding pathologic and molecular concerns in the diagnosis and treatment of breast cancer? (15 mins)
- Component 2: How Do We Treat Patients With Early-Stage Breast Cancer? (15 mins)
- Component 3: What Therapies and Strategies Are Appropriate In Treating Patients with Locally Advanced and Metastatic Breast Cancer? (15 mins)
- Conclusion (5 mins)
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Medical Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.
Method of Participation
To receive acknowledgement of participation for this CME/CE-certified activity, you must complete the evaluation and pass the posttest online with a score of 65% or better in a maximum of 4 attempts. You may print and/or download your certificate upon completion.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Edith A. Perez, MD, has no real or apparent conflicts of interest to report.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Deborah Middleton, MS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
3. Appropriateness of patient care recommendations made to learners
Jointly provided by
This activity is supported by an independent educational grant from Genentech, Inc. For further information concerning Genentech grant funding, visit www.gene.com/good/grants-giving/imed.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
